Special Issue "SARS-CoV-2: Vaccine Design and Host Immunity"
Deadline for manuscript submissions: 15 December 2023 | Viewed by 2052
Interests: cancer; autoimmunity; mental health; vaccines; exercise; infectious diseases; drugs; healthy aging; bioactives
Special Issues, Collections and Topics in MDPI journals
Special Issue in Cancers: Cancer Vaccines: Research and Applications
Special Issue in Vaccines: Therapeutic Approaches for Type 1 and Type 2 Diabetes
Special Issue in Brain Sciences: Advances in Multiple Sclerosis Research—Series I
Special Issue in Vaccines: Multiple Sclerosis and Its Complications: Clinical Trials
Special Issue in Brain Sciences: Advances in Multiple Sclerosis Research—Series II
Special Issue in Vaccines: Vaccines for Infectious and Chronic Diseases
Special Issue in Biologics: Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines
Special Issue in Vaccines: Multiple Sclerosis, Complications and Therapeutics 2.0
Special Issue in Molecules: Advances in Research of Short Peptides II
Special Issue in Biologics: Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes
Special Issue in Cancers: Mucins and Cancers
Special Issue in Cancers: Checkpoint Markers and Cancer Microenvironment: What Do We Know?
Special Issue in International Journal of Molecular Sciences: Chronic Diseases: Gut-Brain-Immune-Microbiome Axis
Special Issue in International Journal of Molecular Sciences: Mechanisms and Interventions for Neurological and Psychological Disorders
Special Issue in Vaccines: Vaccines for Infectious and Chronic Diseases 2.0
Special Issue in Biomedicines: Bioactive Compounds in Chronic Diseases
Special Issue in International Journal of Molecular Sciences: Mechanisms and Interventions for Neurological and Psychological Disorders 2.0
Special Issue in Biologics: Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines - Part II
Topics: Inflammation: The Cause of All Diseases
Topics: Recent Advances in Healthy Ageing
Topics: Inflammation: The Cause of all Diseases 2.0
Vaccines save between 2 and 3 million lives each year. Vaccines alone were responsible for eradicating smallpox, and since the development of the first formal vaccine in the 1700s, over 30 different infectious diseases are prevented with vaccines, such as, polio, meningitis, tetanus, chickenpox, human papilloma virus, and, more recently, COVID-19. Various techniques are used to develop vaccines, including peptide-, protein-, DNA-, mRNA-, viral-vector-, cellular-, or live-attenuated-virus-based vaccines. In addition, novel delivery systems and adjuvants are incorporated into vaccine design for the enhanced stimulation of humoral and cellular immunity.
Since the advent of the current pandemic, SARS-CoV-2, the causative agent of the coronavirus disease (COVID-19), has led to millions of cases and deaths worldwide. The development of effective therapeutics is an urgent global priority to stop the spread of COVID-19 infections and prevent further fatalities. As such, several vaccine platforms have been designed with significant pre-clinical, human clinical trials and roll-outs.
In this Special Issue of Viruses, the focus will be on the development of vaccine platforms with effectiveness data from in vitro, in vivo, in silico, pre-clinical, and human clinical trials. Long term protection studies of roll-out vaccines are also welcome.
This Special Issue will include reviews and original research papers on vaccine design and host immunity against the SARS-CoV-2 virus which causes COVID-19.
Prof. Dr. Vasso Apostolopoulos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- vaccine platforms
- peptide-based vaccines
- synthetic-based vaccines
- protein-based vaccines
- DNA-based vaccines
- viral-vector-based vaccines
- live-attenuated-based vaccines
- mRNA-based vaccines
- dendritic-cells-based vaccines
- antigen presenting cell targeted vaccines
- cell-penetrating peptide-based vaccines
- nanoparticle-based vaccines
- cellular immunity
- humoral immunity
- neutralizing antibodies